Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis
详细信息 查看全文
- 作者：Alastair K. Denniston ; Gary N. Holland ; Andrej Kidess…
- 关键词：Uveitis ; Clinical trials ; Outcome measures ; Endpoints ; Composite endpoints
- 刊名：Orphanet Journal of Rare Diseases
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：10
- 期：1
- 全文大小：893 KB
- 刊物主题：Medicine/Public Health, general; Pharmacology/Toxicology; Medicinal Chemistry;
- 出版者：BioMed Central
- ISSN：1750-1172
文摘
Background Uveitis describes a heterogeneous group of conditions characterized by intraocular inflammation. Since most of the sight-threatening forms of uveitis are individually rare, there has been an increasing tendency for clinical trials to group distinct uveitis syndromes together despite clear variations in phenotype which may reflect real aetiological and pathogenetic differences. Furthermore this grouping of distinct syndromes, and the range of manifestations within each uveitis syndrome, leads to a wide range of possible outcome measures. In this study we wished to review the degree of consensus or otherwise in the choice of primary outcome measures for registered clinical trials related to uveitis.